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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To evaluate the effects of lifestyle interventions in treating women with gestational diabetes.
B A C K G R O U N D
The original review on Treatments for gestational diabetes (Alwan
2009) has been split into three new reviews due to the complexity
of the included interventions. The following new review protocols
are underway.
Lifestyle interventions for the treatment of women with gestational
diabetes (this review)
Oral anti-diabetic pharmacological therapies for the treatment of
women with gestational diabetes
Insulin for the treatment of women with gestational diabetes
There will be similarities in the background, methods and out-
comes between these three systematic reviews. Portions of the
methods section of this protocol are based on a standard template
used by the Cochrane Pregnancy and Childbirth Review Group.
Description of the condition
Gestational diabetes mellitus (GDM), often referred to as gesta-
tional diabetes can be defined as ’glucose intolerance or hyper-
glycaemia (high blood glucose concentration) with onset or first
recognition during pregnancy’ (WHO 1999). GDM occurs when
the body is unable to make enough insulin to meet the extra needs
in pregnancy. The high blood sugars associated with GDM will
usually return to normal after the birth of the baby. However, there
is currently no universally accepted diagnostic criteria (ACOG
2013; Coustan 2010; HAPO 2008; Hoffman 1998; IADPSG
2010;Metzger 1998; NICE 2015). GDMmay include previously
undetected type 1 diabetes, type 2 diabetes or diabetes present-
ing only during pregnancy and not identified through early (first
trimester) pregnancy screening (HAPO 2008; IADPSG 2010;
Metzger 1998; Nankervis 2014; WHO 2014). Women meeting
diagnostic criteria for overt diabetes would not be considered to
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have GDM, however until recently, confirmation of overt diabetes
was only possible in the postpartum period. With the uptake of
early screening in the first trimester with glycated or glycosylated
haemoglobin - HbA1C (glycated or glycosylated haemoglobin is
a form of haemoglobin measured primarily to identify the average
plasma glucose concentration over a period of time), more women
with overt diabetes will be diagnosed and treated appropriately
(Ministry of Health 2014 - New Zealand).
GDM is one of the most common pregnancy complications and
the prevalence is rising worldwide with 1% to 36% of pregnan-
cies being affected (Bottalico 2007; Cundy 2014; Duran 2014;
Ferrara 2007; Kleinwechter 2014; NICE 2015; Tran 2013). The
prevalence of GDM is likely to continue to increase along with
the increasing prevalence of maternal obesity and associated type
2 diabetes mellitus (Bottalico 2007; Mulla 2010).
Screening and diagnosis of GDM
Regardless of whether universal or selective (risk-factor) screen-
ing with a 50 gram (g) oral glucose challenge test is used, diag-
nosis of GDM is usually based on either a 75 g two-hour oral
glucose tolerance test (OGTT) or a 100 g three-hour OGTT
(ADA2013; IADPSG2010;Nankervis 2014;NICE 2015;WHO
1999; WHO 2014). Recommendations regarding diagnostic cri-
teria vary nationally and internationally (Table 1), and these diag-
nostic criteria have changed over time, sometimes due to changing
understanding about the effects of hyperglycaemia on pregnancy
and infant outcomes (Coustan 2010), but also because of a lack of
evidence clearly demonstrating the clinical and cost-effectiveness
of one criterion over another.
The Hyperglycaemia and Adverse Pregnancy Outcomes (HAPO)
study (HAPO 2008) was a large, international observational study
that reported graded linear associations in the odds of several
GDM-associated adverse outcomes and glucose levels at OGTT,
with no clear threshold identified at which risk increased substan-
tially. The International Association of the Diabetes and Preg-
nancy Study Groups (IADPSG) recommended diagnostic criteria
using data from the HAPO study (IADPSG 2010). Applying the
IADPSG criteria in most health environments will increase the
number of women diagnosed with GDM. A study conducted in
Vietnam showed that depending on the criteria used, the diag-
nosis of GDM varied between 5.9% (American Diabetes Asso-
ciation - ADA), 20.4% (International Association of Diabetes in
Pregnancy Study Groups - IADPSG), 20.8% (Australasian Dia-
betes in Pregnancy Society - ADIPS), and up to 24.3% (World
Health Organization - WHO) (Tran 2013). A Bulgarian study
also reported differences in prevalence based on the diagnostic cri-
teria ranging from 10.8% (European Association for the Study
of Diabetes - EASD), 13.5% (ADA), 16.2% (New Zealand Soci-
ety for the Study of Diabetes - NZSSD), 17.1% (WHO), 21.2%
(ADIPS), 31.6% (IADPSG) (Boyadzhieva 2012).
Pathophysiology of GDM
Normal pregnancy is associated with significant changes in ma-
ternal metabolism (Lain 2007). In early pregnancy, oestrogen and
progesterone stimulate maternal beta-cell hyperplasia and insulin
secretion, which promotes maternal nutrient storage (adipose and
hepatic glycogen) to support later fetal growth. At this stage, in-
sulin sensitivity is maintained or may even increase. However, as
pregnancy progresses, whole-body insulin sensitivity steadily de-
creases, such that by the third trimester it is reduced by almost half
(Barbour 2007). Several factors contribute to this, including pla-
cental hormones (human placental lactogen and placental growth
hormone), cytokines released from adipocytes (IL-6, TNF-alpha),
increased free fatty acids and lower adiponectin concentrations
(Clapp2006;Devlieger 2008). This results in decreased post-pran-
dial peripheral glucose disposal by up to 40% to 60% (Barbour
2007). Because glucose is transported to the fetus by facilitated
diffusion, this state of physiological insulin resistance promotes
fetal glucose uptake, a principal oxidative fuel and carbon source
for the growing fetus. In normal pregnancy, maternal glycaemia is
maintained by a significant increase in insulin secretion of up to
200% to 250% (Barbour 2007; Lain 2007; Suman Rao 2013).
Regulation of fetal glucose metabolism requires (1) the mainte-
nance of maternal glucose concentration through increasing ma-
ternal glucose production, and at the same time, developing ma-
ternal glucose intolerance and insulin resistance, (2) transfer of
glucose to the fetus across the placenta, and (3) production of fe-
tal insulin and uptake of glucose into adipose tissue and skeletal
muscle (Suman Rao 2013).
Women with GDM have further reductions in insulin signalling,
and glucose uptake is decreased beyond that of normal pregnancy
(Barbour 2007). This results in glucose intolerance, though gly-
caemia in pregnancy represents a continuum. InGDM, the steeper
maternal-fetal glucose gradient, especially post-prandial, leads to
increased fetal glucose uptake which stimulates fetal insulin se-
cretion. Insulin is a key fetal anabolic hormone and hyperin-
sulinaemia promotes fetal overgrowth leading to large-for-gesta-
tional age (LGA) infants, macrosomia, and possible organ damage
(Catalano 2003; Ju 2008; Metzger 2008; Reece 2009).
Women with GDM also have increased circulating inflammatory
cytokines and lower adiponectin concentrations leading to in-
creased lipolysis and fatty acid concentrations. Placental transfer
of free fatty acids contributes to increased fetal adiposity, indepen-
dent of glucose uptake (Knopp 1985). Thus, even women with
well-controlled GDM still have an increased risk of fetal macro-
somia (Langer 2005).
Risk factors associated with GDM
A variety of factors have been associated with an increased risk of
developing GDM. Non-modifiable risk factors include advanced
maternal age (Chamberlain 2013; Morisset 2010), high parity,
non-Caucasian race or ethnicity (in particular SouthAsian,Middle
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Eastern), family history of diabetes mellitus, maternal high or low
birthweight, polycystic ovarian syndrome (Cypryk 2008; Petry
2010; Solomon 1997), a history of having a previous macrosomic
infant (birthweight 4000 g ormore) and previous history of GDM
(Petry 2010).
Modifiable risk factors include physical inactivity (Chasan-Taber
2008), having a low-fibre and high-glycaemic load diet (Zhang
2006), maternal overweight (body mass index (BMI) equal to or
greater than 25 kg/m²) or obesity (equal to or greater than 30 kg/
m²) (Kim 2010a), and excessive weight gain during pregnancy, es-
pecially for those who are already overweight or obese (Hedderson
2010).
Clinical outcomes for women with pregnancy
hyperglycaemia
Adverse outcomes have been consistently reported at higher rates
in women diagnosed with GDM and their infants compared with
women without GDM (Crowther 2005; Landon 2009; Metzger
2008; Reece 2009).
Women with GDM have an increased risk of developing pre-
eclampsia, are more likely to have their labour induced (Anderberg
2010; Crowther 2005; Ju 2008; Landon 2009; Metzger 2008),
and giving birth by caesarean section (Landon 2009; Metzger
2008). The incidence of uterine rupture, shoulder dystocia and
perineal lacerations is increased in women with GDM due to the
increased likelihood of having a LGAormacrosomic baby (Jastrow
2010).Women who have experiencedGDM are at a greater risk of
metabolic dysfunction in later life (Shah 2008; Vohr 2008), with
a crude cumulative incidence of type 2 diabetes of 10% to 20%
within 10 years (Bellamy 2009; Kim 2002), but up to 50% when
adjusted for retention and length of follow-up (Kim 2002).
Neonatal, infant and later outcomes related to
pregnancy hyperglycaemia
A significant adverse health outcome for babies born to mothers
with GDM is being born LGA or macrosomic (Catalano 2003;
Crowther 2005; Landon 2009;Metzger 2008; Reece 2009), which
increases the risk of birth injury, including shoulder dystocia, peri-
natal asphyxia, bone fractures and nerve palsies (Esakoff 2009;
Henriksen 2008; Langer 2005;Metzger 2008).Other adverse out-
comes which are increased for babies born to women with GDM
include respiratory distress syndrome, hypoglycaemia (which if
prolonged can cause brain injury), hyperbilirubinaemia, hyper-
trophic cardiomyopathy, hypocalcaemia, hypomagnesaemia, poly-
cythaemia and admission to the neonatal nursery (Metzger 2008;
Reece 2009).
Babies born to women with GDM, compared with babies born
to women without GDM, have significantly greater skinfold mea-
sures and fat mass (Catalano 2003), have greater adiposity (Pettitt
1985; Pettitt 1993), and are more likely to develop early over-
weight or obesity, type 2 diabetes (Hillier 2007; Pettitt 1993;
Whincup 2008), or metabolic syndrome (a cluster of risk factors
defined by the occurrence of three of the following: obesity, hy-
pertension, hypertriglyceridaemia and low concentration of high-
density lipoprotein (HDL) cholesterol) in childhood, adolescence
or adulthood (Guerrero-Romero 2010; Harder 2009).
The development of the metabolic syndrome during childhood is
a risk factor for the development of adult type 2 diabetes at 25
to 30 years of age (Morrison 2008). These health problems repeat
across generations (Dabelea 2005; Mulla 2010) and are important
from a public health perspective, because with each generation the
prevalence of diabetes increases. For longer-term outcomes there
is some evidence to suggest a link between maternal gestational
diabetes and developmental delay (Dione 2008) and increased risk
of Attention Deficit Hyperacticivity Disorder (Nomura 2012).
Description of the intervention
GDM management aims to optimise glycaemic control and con-
sequently improve pregnancy outcomes (Kim 2010b). Providing
dietary and lifestyle advice is usually recommended as the primary
therapeutic strategy for women with GDM (ACOG 2013; ADA
2015a; Hoffman 1998; NICE 2015). If diet and lifestyle man-
agement alone are insufficient to achieve targets for maternal gly-
caemic control, insulin therapy or oral anti-diabetic pharmacolog-
ical therapies such as glibenclamide and metformin can be added
(ACOG 2013; ADA 2013; Hoffman 1998; NICE 2015; Silva
2010; Simmons 2004). As part of GDM management, maternal
glucose monitoring and ultrasonography are advised to monitor
the effectiveness of treatment and to guide care for birth (ACOG
2013; Hoffman 1998; NICE 2015). However, treatment recom-
mendations differ across countries, for example, serial ultrasonog-
raphy is not recommended to guide treatment management in the
New Zealand Ministry of Health guidelines (Ministry of Health
2014).
Dietary intervention for managing GDM
Diet therapy is the primary strategy for managing GDM. El-
evated blood glucose concentrations, in particular elevations in
post-prandial glucose are associated with adverse pregnancy out-
comes in GDM (de Veciana 1995). The role of head-to-head di-
etary interventions for treatment of women with GDM has been
described in the Cochrane systematic review by Han 2013 and
will not be included in this systematic review.
Carbohydrate-containing foods are important sources of energy,
vitamins, minerals and fibre and are the main nutrient affecting
blood glucose concentrations (Reader 2007). Blood glucose con-
centrations are affected by both total amount and type of carbohy-
drates consumed (Reader 2007). Glycaemic index (GI) is a rank-
ing of the effects of carbohydrates on blood glucose concentra-
tions (Jenkins 1981). Foods with a low GI (less than 55) produce
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a lower post-prandial glucose elevation and area under the glu-
cose curve; foods with a high GI (more than 70) produce a rapid
increase in post-prandial blood glucose concentrations (Jenkins
1981). Outside of pregnancy, consumption of low-GI diets by
people with diabetes seems to help lower glycated or glycosylated
haemoglobin - HbA1C (Thomas 2010). Use of low-GI diets in
GDM management seems to be beneficial in reducing the need
for insulin, though the evidence is limited (Moses 2009). Polyun-
saturated fatty acids may be protective against impaired glucose
tolerance, while saturated fatty acids can increase glucose and in-
sulin concentrations in women with GDM (Ilic 1999). Reducing
blood lipid concentrations may improve glycaemic control and
pregnancy outcomes in GDM (Barrett 2014). However, the spe-
cific amount and sources of fat that are beneficial for GDMman-
agement are not clear (Kim 2010b). Therefore, recommendations
on the fat intake for women with GDM have not yet been pro-
mulgated (ACOG 2013; Hoffman 1998; Metzger 2007; (New
Zealand) Ministry of Health 2014; NICE 2015). Recommenda-
tions on the intake of other nutrients for women with GDM are
usually based on the general recommendations for people with
diabetes mellitus outside pregnancy (Cheung 2009).
Physical activity during pregnancy for managing GDM
The role of supplementary physical activity interventions with
no additional physical activity for the management of glycaemic
control in women with diabetes in pregnancy (including GDM)
was one of the comparisons described in the Cochrane review by
Ceysens 2006. Innon-pregnantwomenwith type 2diabetes, phys-
ical activity (in addition to diet and insulin) helped to normalise
blood glucose levels (Tuomilehto 2001). Caution is required when
generalising this evidence to pregnant women but it potentially
suggests that during pregnancy mild exercise could reduce the risk
of complications related to high blood glucose and high insulin
levels, including macrosomia, birth trauma, respiratory distress,
neonatal hypoglycaemia and hypocalcaemia. Exercise interven-
tions alone for treating women with gestational diabetes will not
be included in this systematic review.
Appropriate weight gain during pregnancy
Interventions for preventing excessive weight gain in pregnancy
(diet or exercise or both) have been described in the Cochrane
systematic review by Muktabhant 2015, which included 65 ran-
domised controlled trials of which seven recruited women who
were at high risk of gestational diabetes. Given the high prevalence
of overweight and obesity in women with GDM, dietary interven-
tions for appropriate pregnancy weight gain are routinely included
as a part of nutritional management of GDM (Kim 2010b). Small
reductions in weight improve glycaemic control (ACOG 2005),
but the implications in pregnancy for the mother and fetus are
unclear.
In 2009, the American Institute of Medicine updated its’ guide-
lines for weight gain during pregnancy. Guidance is stratified by
pre-pregnancy BMI, i.e. women with a pre-pregnancy BMI be-
tween 25 and 29.9 kg/m² should aim for 6.8 to 11.4 kgweight gain
and those with pre-pregnancy BMI of 30 kg/m² or more should
aim for 5 to 9 kg weight gain (IOM 2009). However, the degree of
energy restriction for pre-pregnancy overweight and obese women
to achieve these weight gain goals is unknown and is based on
observational data (Kim 2010b).
Dietary interventions provided for women with GDM should
ensure adequate nutrients for normal fetal growth and maternal
health, but not induce weight loss or excessive weight gain during
pregnancy; themain aim however is to promote optimal glycaemic
control (ACOG 2013; Hoffman 1998; Metzger 2007; NICE
2015).
Combined dietary intervention and physical activity
during pregnancy for managing GDM
Some interventions may involve a combination of dietary and
physical activity modalities. Regular physical activity may help
normalise maternal blood glucose for pregnant women with ges-
tational diabetes and in combination with dietary interventions
may reduce the need for oral anti-diabetic agents or insulin. As
women with gestational diabetes are at increased risk of develop-
ing type 2 diabetes in the future, regular physical activity may also
help reduce the risk of this long-term complication (Tuomilehto
2011).
Other interventions during pregnancy for managing
GDM
There may be other interventions, including psychological ap-
proaches that may be used independently or alongside physical
activity or dietary modalities such as mindfulness eating, yoga or
spiritual support.
How the intervention might work
Role of diet
A carbohydrate-controlled diet (with carbohydrates distributed
evenly throughout the day) that provides adequate nutrition,
alongside glycaemic control and avoids ketonuria (ketones are pro-
duced when stored fat is utilised to produce energy in the absence
of glucose) is thought to be optimal to reduce complications asso-
ciatedwith gestational diabetes (Dornhorst 2002).Other elements
of diet such as fat and fibre are also thought to influence maternal
blood glucose concentrations (Zhang 2006). Excess fetal growth
is most effectively limited by low post-prandial maternal glucose
levels (de Veciana 1995; Dornhorst 2002; Harmon 2011; Rowan
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2011; Weisz 2005). Dietary advice in the second trimester, as in-
sulin resistance is developing may help reduce the risk of adverse
outcomes associated with GDM (Dornhorst 2002).
Role of physical activity
Insulin sensitivity in skeletal muscle is related to the degree of
physical activity, and therefore, physical activity interventions may
improve insulin sensitivity and glucose control in individuals with
diabetes (Asano 2014).
Glucose enters skeletal muscle cells via facilitated diffusion
through a glucose transporter (GLUT4). Peripheral clearance of
glucose in skeletalmuscle depends onbloodflow tomuscle, expres-
sion of GLUT4 transporters and intracellular utilisation of glucose
through glycolysis and glycogenesis. Translocation of the GLUT4
transporter is induced by insulin and insulin-independent mecha-
nisms (Richter 2001). Exercise increases glucose uptake in skeletal
muscle (Asano 2014), and improves glucose homeostasis and in-
sulin sensitivity in skeletal muscle. Exercise potentiates most of the
insulin-mediated post-receptor events that lead to an increased ex-
pression of GLUT4, and GLUT4 translocation from intracellular
stores to the muscle membrane. These exercise-induced improve-
ments in glucose uptake, however, are not limited to changes in
GLUT4 expression. The improvements in insulin sensitivity after
regular exercise may be related to changes in expression and/or ac-
tivity of proteins involved in insulin signal transduction in skeletal
muscle. As such, the enhanced glucose uptake in skeletal muscle
attributed to exercise might be related to an increased expression
and activity of key proteins for insulin signalling such as insulin
receptor, insulin receptor substrate, and phosphatidylinositol 3-
kinase (Chibalin 2000; Dela 1993; Hjeltnes 1998). Physical ac-
tivity improves blood supply to the active skeletal muscles (Jensen
2004), counteracts the ability of lipids to induce insulin resistance
(Schenk 2005), and modifies the hormonal regulation of hepatic
glucose output. These exercise-induced alterations in muscle glu-
cose handling explain most of the insulin-sensitising and diabetes-
preventing effects of exercise, and partly explain why the many
defects of insulin action observed in type 2 diabetes and insulin
resistance are reversed by the effects of exercise (Zierath 2002).
Self-monitoring of blood glucose
Self-monitoring of blood glucose is performed by most women
with GDM. Evidence has suggested that self-monitoring between
four and seven times per day (including fasting and post-prandial
measurements) can contribute to improvedmaternal and perinatal
outcomes (ADA 2001) and is likely to be most effective when
combined with effective treatment.
Why it is important to do this review
GDM affects a significant proportion of pregnant women and
the prevalence is increasing worldwide (Bottalico 2007; Dabelea
2005; Mulla 2010). GDM is associated with an increased risk of
a range of adverse pregnancy outcomes and these adverse health
outcomes repeat across generations (Metzger 2008; Mulla 2010),
which has important implications for the future. Providing dietary
and lifestyle advice is usually recommended as the primary ther-
apeutic strategy for women with GDM (ACOG 2013; Hoffman
1998; (New Zealand) Ministry of Health 2014; NICE 2015).
’Different types of dietary advice for women with gestational diabetes
mellitus’ (Han 2013). This review examined the effects of two or
more forms of the same type of dietary interventions compared
with each other for treating women with GDM, i.e. standard di-
etary advice compared with individualised dietary advice, individ-
ual dietary education sessions compared with group dietary edu-
cation sessions, single dietary counselling session compared with
multiple dietary counselling sessions.
’Exercise for diabetic pregnant women’ (Ceysens 2006). This review
evaluated the effects of physical activity interventions +/- dietary
interventions compared with no additional physical activity in-
tervention for women with diabetes in pregnancy and the trials
included in the review recruited women with gestational diabetes.
O B J E C T I V E S
To evaluate the effects of lifestyle interventions in treating women
with gestational diabetes.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include published or unpublished randomised controlled
trials or cluster-randomised trials in full text or abstract format.
Quasi-randomised and cross-over trials will be excluded. Confer-
ence abstracts will be handled in the same way as full-text publi-
cations.
Types of participants
Participants will be pregnant women diagnosed with gestational
diabetes (diagnosis as defined by the individual trial).Womenwith
known type 1 or type 2 diabetes will be excluded.
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Types of interventions
We will include randomised trials comparing lifestyle interven-
tions (as defined by trialists) with:
• expectant management, standard care;
• other lifestyle intervention or combination of lifestyle
interventions not described above.
The aim of the interventions will be to maintain maternal gly-
caemic targets during pregnancy in women with gestational dia-
betes.
Lifestyle interventions should include a combination of at least
two or more of the following interventions:
• diet;
• physical activity;
• education;
• behavioural change;
• regimens of self-monitoring of blood glucose;
• other intervention not previously specified.
These interventions may or may not require adjunctive pharma-
cotherapy (oral anti-diabetic pharmacological therapies, insulin)
used to treat women with gestational diabetes.
Interventions examining the comparison of different dietary inter-
ventions or the effects of exercise alone will not be included in this
review as they are already included in other Cochrane systematic
reviews (Han 2013 and Ceysens 2006 respectively).
Types of outcome measures
Primary outcomes
Maternal
• Hypertensive disorders of pregnancy (including pre-
eclampsia, pregnancy-induced hypertension, eclampsia as
defined by trialists)
• Caesarean section
• Development of type 2 diabetes
Neonatal
• Perinatal (fetal and neonatal death) and later infant
mortality
• Large-for-gestational age (LGA) (as defined by trialists)
• Death or serious morbidity composite (variously defined by
trials, e.g. perinatal or infant death, shoulder dystocia, bone
fracture or nerve palsy)
• Neurosensory disability in later childhood (as defined by
trialists)
Secondary outcomes
Maternal
• Use of additional pharmacotherapy
• Maternal hypoglycaemia (as defined by trialists)
• Glycaemic control during/end of treatment (as defined by
trialists)
• Weight gain in pregnancy
• Adherence to the intervention
• Induction of labour
• Placental abruption
• Postpartum haemorrhage (as defined by trialists)
• Postpartum infection
• Perineal trauma/tearing
• Breastfeeding at discharge, six weeks postpartum, six
months or longer
• Maternal mortality
• Sense of well-being and quality of life
• Behavioural changes associated with the intervention
• Views of the intervention
• Relevant biomarker changes associated with the
intervention (including adiponectin, free fatty acids,
triglycerides, high-density lipoproteins, low-density lipoproteins,
insulin)
Long-term outcomes for mother
• Postnatal depression
• Body mass index (BMI)
• Postnatal weight retention or return to pre-pregnancy
weight
• Type 1 diabetes
• Type 2 diabetes
• Impaired glucose tolerance
• Subsequent gestational diabetes
• Cardiovascular health (as defined by trialists including
blood pressure, hypertension, cardiovascular disease, metabolic
syndrome)
Fetal/neonatal outcomes
• Stillbirth
• Neonatal death
• Macrosomia (greater than 4000 g; or as defined by
individual study)
• Small-for-gestational (SGA) age (as defined by trialists)
• Birth trauma (shoulder dystocia, bone fracture, nerve palsy)
• Gestational age at birth
• Preterm birth (< 37 weeks’ gestation; and < 32 weeks’
gestation)
• Five-minute Apgar < seven
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• Birthweight and z score
• Head circumference and z score
• Length and z score
• Ponderal index
• Adiposity (including skinfold thickness measurements
(mm); fat mass)
• Neonatal hypoglycaemia (as defined by trialists)
• Respiratory distress syndrome
• Neonatal jaundice (hyperbilirubinaemia) (as defined by
trialists)
• Hypocalcaemia (as defined by trialists)
• Polycythaemia (as defined by trialists)
• Relevant biomarker changes associated with the
intervention (including insulin, cord c-peptide)
Later infant/childhood outcomes
• Weight and z scores
• Height and z scores
• Head circumference and z scores
• Adiposity (including BMI, skinfold thickness, fat mass)
• Educational attainment
• Blood pressure
• Type 1 diabetes
• Type 2 diabetes
• Impaired glucose tolerance
• Dyslipidaemia or metabolic syndrome
Child as an adult outcomes
• Weight
• Height
• Adiposity (including BMI, skinfold thickness, fat mass)
• Cardiovascular health (as defined by trialists including
blood pressure, hypertension, cardiovascular disease, metabolic
syndrome)
• Employment, education and social status/achievement
• Dyslipidaemia or metabolic syndrome
• Type 1 diabetes
• Type 2 diabetes
• Impaired glucose tolerance
Health service use
• Number of antenatal visits or admissions
• Number of hospital or health professional visits (including
midwife, obstetrician, physician, dietician, diabetic nurse)
• Admission to neonatal intensive care unit/nursery
• Duration of stay in neonatal intensive care unit or special
care baby unit
• Length of antenatal stay
• Length of postnatal stay (maternal)
• Length of postnatal stay (baby)
• Cost of maternal care
• Cost of offspring care
• Costs associated with the intervention
• Costs to families associated with the management provided
• Cost of dietary monitoring (e.g. diet journals, dietician,
nurse visits, etc)
• Costs to families - change of diet, extra antenatal visits
• Extra use of healthcare services (consultations, blood
glucose monitoring, length and number of antenatal visits)
• Women’s view of treatment advice
Search methods for identification of studies
The following methods section of this protocol is based on a stan-
dard template used by the Cochrane Pregnancy and Childbirth
Group.
Electronic searches
We will contact the Trials Search Co-ordinator to search the
Cochrane Pregnancy and Childbirth Group’s Trials Register.
The Cochrane Pregnancy and Childbirth Group’s Trials Register
is maintained by the Trials Search Co-ordinator and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE (Ovid);
3. weekly searches of Embase (Ovid);
4. monthly searches of CINAHL (EBSCO);
5. handsearches of 30 journals and the proceedings of major
conferences;
6. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Details of the search strategies for CENTRAL, MEDLINE, Em-
base and CINAHL, the list of handsearched journals and confer-
ence proceedings, and the list of journals reviewed via the current
awareness service can be found in the ‘Specialized Register’ section
within the editorial information about the Cochrane Pregnancy
and Childbirth Group.
Trials identified through the searching activities described above
are each assigned to a review topic (or topics). The Trials Search
Co-ordinator searches the register for each review using the topic
list rather than keywords.
In addition, we will search ClinicalTrials.gov and the WHO In-
ternational Clinical Trials Registry Platform (ICTRP) for unpub-
lished, planned and ongoing trial reports. The search terms we
plan to use are given in (Appendix 1).
Searching other resources
We will search the reference lists of retrieved studies.
We will not apply any language or date restrictions.
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Data collection and analysis
The following methods section of this protocol is based on a stan-
dard template used by the Cochrane Pregnancy and Childbirth
Group.
Selection of studies
Two review authors will independently assess for inclusion all the
potential studies we identify as a result of the search strategy. We
will resolve any disagreement through discussion or, if required,
we will consult a third person.
We will create a study flow diagram to map out the number of
records identified, included and excluded.
Data extraction and management
We will design a form to extract data. For eligible studies, two
review authors will extract the data using the agreed form.We will
resolve discrepancies through discussion or, if required, we will
consult a third person. We will enter data into Review Manager
software (RevMan 2014) and check for accuracy. When informa-
tion regarding any of the above is unclear, we will attempt to con-
tact authors of the original reports to provide further details.
Assessment of risk of bias in included studies
Two review authors will independently assess risk of bias for
each randomised study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We will resolve any disagreement by discussion or by involving
a third assessor. Where cluster-randomised trials are included we
will refer to theHandbook sections 16.3.2 and 16.4.3 for assessing
bias.
(1) Random sequence generation (checking for possible
selection bias)
We will describe for each included study the method used to gen-
erate the allocation sequence in sufficient detail to allow an assess-
ment of whether it should produce comparable groups.
We will assess the method as:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number);
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection
bias)
We will describe for each included study the method used to con-
ceal allocation to interventions prior to assignment and will assess
whether intervention allocation could have been foreseen in ad-
vance of, or during recruitment, or changed after assignment.
We will assess the methods as:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
We will describe for each included study the methods used, if
any, to blind study participants and personnel from knowledge of
which intervention a participant received. We will consider that
studies are at low risk of bias if they were blinded, or if we judge
that the lack of blinding would be unlikely to affect results. We
will assess blinding separately for different outcomes or classes of
outcomes.
We will assess the methods as:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
We will describe for each included study the methods used, if any,
to blind outcome assessors from knowledge of which intervention
a participant received. We will assess blinding separately for dif-
ferent outcomes or classes of outcomes.
We will assess methods used to blind outcome assessment as:
• low, high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
We will describe for each included study, and for each outcome
or class of outcomes, the completeness of data including attrition
and exclusions from the analysis. We will state whether attrition
and exclusions were reported and the numbers included in the
analysis at each stage (compared with the total randomised par-
ticipants), reasons for attrition or exclusion where reported, and
whether missing data were balanced across groups or were related
to outcomes. Where sufficient information is reported, or can be
supplied by the trial authors, we will re-include missing data in
the analyses which we undertake.
We will assess methods as:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ‘as treated’ analysis done with
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substantial departure of intervention received from that assigned
at randomisation);
• unclear risk of bias.
(5) Selective reporting (checking for reporting bias)
We will describe for each included study how we investigated the
possibility of selective outcome reporting bias and what we found.
We will assess the methods as:
• low risk of bias (where it is clear that all of the study’s pre-
specified outcomes and all expected outcomes of interest to the
review have been reported);
• high risk of bias (where not all the study’s pre-specified
outcomes have been reported; one or more reported primary
outcomes were not pre-specified; outcomes of interest are
reported incompletely and so cannot be used; study fails to
include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.
(6) Other bias (checking for bias due to problems not
covered by (1) to (5) above)
We will describe for each included study any important concerns
we have about other possible sources of bias.
We will assess whether each study was free of other problems that
could put it at risk of bias:
• low risk of other bias;
• high risk of other bias;
• unclear whether there is risk of other bias.
(7) Overall risk of bias
We will make explicit judgements about whether studies are at
high risk of bias, according to the criteria given in the Handbook
(Higgins 2011). With reference to (1) to (6) above, we will assess
the likely magnitude and direction of the bias and whether we
consider it is likely to impact on the findings. We will explore the
impact of the level of bias through undertaking sensitivity analyses
- see Sensitivity analysis.
Assessment of the quality of the evidence using the GRADE
approach
The quality of the evidence will be assessed using the GRADE
approach as outlined in the GRADE handbook in order to assess
the quality of the body of evidence relating to the following out-
comes. We have selected up to a maximum of seven outcomes for
themother and seven for the infant covering both short- and long-
term outcomes for the main comparisons.
Maternal outcomes
• Hypertensive disorders of pregnancy (including pre-
eclampsia, pregnancy-induced hypertension, eclampsia)
• Caesarean section
• Development of type 2 diabetes
• Perineal trauma
• Return to pre-pregnancy weight
• Postnatal depression
• Induction of labour
Neonatal/child/adult outcomes
• LGA
• Perinatal mortality
• Death or morbidity composite (variously defined by studies,
e.g. infant death, shoulder dystocia, bone fracture or nerve palsy)
• Neonatal hypoglycaemia
• Adiposity
• Diabetes
• Neurosensory disability
We will use the GRADEpro Guideline Development Tool to im-
port data from Review Manager 5.3 (RevMan 2014) in order to
create ’Summary of findings’ tables. A summary of the interven-
tion effect and a measure of quality for each of the above outcomes
will be produced using the GRADE approach. The GRADE ap-
proach uses five considerations (study limitations, consistency of
effect, imprecision, indirectness and publication bias) to assess the
quality of the body of evidence for each outcome. The evidence
can be downgraded from ’high quality’ by one level for serious (or
by two levels for very serious) limitations, depending on assess-
ments for risk of bias, indirectness of evidence, serious inconsis-
tency, imprecision of effect estimates or potential publication bias.
Measures of treatment effect
Dichotomous data
For dichotomous data, we will present results as summary risk
ratio with 95% confidence intervals.
Continuous data
For continuous data, we will use the mean difference if outcomes
are measured in the same way between trials. We will use the
standardised mean difference to combine trials that measure the
same outcome, but use different methods.
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Unit of analysis issues
Cluster-randomised trials
Wewill include cluster-randomised trials in the analyses alongwith
individually-randomised trials. We will make adjustments using
themethods described in theHandbook [Section 16.3.4 or 16.3.6]
using an estimate of the intra-cluster correlation co-efficient (ICC)
derived from the trial (if possible), from a similar trial or from a
study of a similar population. If we use ICCs from other sources,
we will report this and conduct sensitivity analyses to investigate
the effect of variation in the ICC. We will consider it reasonable
to combine the results from both cluster-randomised trials and
individually-randomised trials if there is little heterogeneity be-
tween the study designs and the interaction between the effect of
intervention and the choice of randomisation unit is considered
to be unlikely. If cluster-randomised trials are included, we will
seek statistical advice on appropriate analysis to enable inclusion
of data in the meta-analyses.
Other unit of analysis issues
Multiple pregnancy
There may be unit of analysis issues that arise when the women
randomised have a multiple pregnancy. We will present maternal
data as per woman randomised and neonatal data per infant.
Multiple-arm studies
Where a trial has multiple intervention arms we will avoid ’double
counting’ of participants by combining groups to create a single
pair-wise comparison if possible. Where this is not possible, we
will split the ’shared’ group into two or more groups with smaller
sample size and include two or more (reasonably independent)
comparisons.
Dealing with missing data
For included studies, wewill note levels of attrition.Wewill explore
the impact of including studies with high levels of missing data
(> 20%) in the overall assessment of treatment effect by using
sensitivity analysis.
For all outcomes, we will carry out analyses, as far as possible,
on an intention-to-treat basis, i.e. we will attempt to include all
participants randomised to each group in the analyses, and all
participants will be analysed in the group to which they were
allocated, regardless of whether or not they received the allocated
intervention. The denominator for each outcome in each trial
will be the number randomised minus any participants whose
outcomes are known to be missing.
Assessment of heterogeneity
We will assess statistical heterogeneity in each meta-analysis using
the Tau², I² and Chi² statistics. We will regard heterogeneity as
substantial if an I² is greater than 30% and either a Tau² is greater
than zero, or there is a low P value (less than 0.10) in the Chi² test
for heterogeneity.
Assessment of reporting biases
If there are 10 or more studies in the meta-analysis, we will in-
vestigate reporting biases (such as publication bias) using funnel
plots. We will assess funnel plot asymmetry visually. If asymmetry
is suggested by a visual assessment, we will perform exploratory
analyses to investigate it.
Data synthesis
We will carry out statistical analysis using the Review Manager
software (RevMan 2014). We will use fixed-effect meta-analysis
for combining datawhere it is reasonable to assume that studies are
estimating the same underlying treatment effect: i.e. where trials
are examining the same intervention, and the trials’ populations
and methods are judged sufficiently similar. If there is clinical het-
erogeneity sufficient to expect that the underlying treatment ef-
fects differ between trials, or if substantial statistical heterogeneity
is detected, we will use random-effects meta-analysis to produce
an overall summary, if an average treatment effect across trials is
considered clinically meaningful. The random-effects summary
will be treated as the average of the range of possible treatment
effects and we will discuss the clinical implications of treatment
effects differing between trials. If the average treatment effect is
not clinically meaningful, we will not combine trials.
If we use random-effects analyses, the results will be presented as
the average treatment effect with 95% confidence intervals, and
the estimates of Tau² and I².
Subgroup analysis and investigation of heterogeneity
If we identify substantial heterogeneity, we will investigate it us-
ing subgroup analyses and sensitivity analyses. We will consider
whether an overall summary is meaningful, and if it is, use ran-
dom-effects analysis to produce it.
• Diagnostic test used: ADA 2013, IADPSG 2010, Nankervis
2014 versus ACOG 2013 versus NICE 2015 versus NICE 2008;
WHO 1999; WHO 2014 or Hoffman 1998 versus New Zealand
Ministry of Health 2014 versus other not previously specified
• Timing of diagnosis: early (< 28 weeks’ gestation) versus
late ( ≥ 28 weeks’ gestation)
The following outcomes will be used in subgroup analysis.
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Maternal outcomes
• Pre-eclampsia
• Caesarean section
• Development of type 2 diabetes
Neonatal outcomes
• LGA
• Perinatal mortality
• Death or morbidity composite (variously defined by trials,
e.g. infant death, shoulder dystocia, bone fracture or nerve palsy)
• Neurosensory disability in later childhood (as defined by
trialists)
We will assess subgroup differences by interaction tests available
within RevMan (RevMan 2014). We will report the results of
subgroup analyses quoting the Chi2 statistic and P value, and the
interaction test I² value.
Sensitivity analysis
If there is evidence of significant heterogeneity, we will explore
this by using the quality of the included trials for the primary
outcomes. We will compare trials that have low risk of bias for
allocation concealment with those judged to be of unclear or high
risk of bias, and conference abstracts will be excluded from the
meta-analysis.
We will also investigate the effect of the randomisation unit (i.e.
where we include cluster-randomised trials along with individu-
ally-randomised trials).
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A D D I T I O N A L T A B L E S
Table 1. Examples of diagnostic criteria for gestational diabetes mellitus
Organisation/
professional
body
Screening crite-
ria
Diagnostic criteria
One-
hour oral glucose
challenge test
Oral glucose tol-
erance test
Fasting One hour Two hour Three hour
ADA 2015b* ,
IADPSG 2010*,
ADIPS 2014* (
Nankervis 2014)
; WHO 2014*
- 75 g ≥ 5.1 mmol/L
(≥ 92 mg/dL)
≥ 10mmol/L (≥
180 mg/dL)
≥ 8.5 mmol/L
(≥ 153 mg/dL)
-
ADA 2015b 50 g
(≥ 7.8 mmol/L;
≥ 140 mg/dL)
75 g ≥ 5.1 mmol/L
(≥ 92 mg/dL)
≥ 10mmol/L (≥
180 mg/dL)
≥ 8.5 mmol/L
(≥ 153 mg/dL)
-
ACOG 2013
Carpenter and
Coustanˆ
Na-
tional Diabetes
Data Groupˆ
50 g
(> 7.2 mmol/L;
> 130 mg/dL)
100 g ≥ 5.3 mmol/L
(95 mg/dL)
≥ 10 mmol/L
(180 mg/dL)
≥ 8.6 mmol/L
(155 mg/dL)
≥ 7.8 mmol/L
(140 mg/dL)
50 g
(> 7.8mmol/L; >
140 mg/dL)
100 g ≥ 5.8 mmol/L
(105 mg/dL)
≥ 10.6 mmol/L
(190 mg/dL)
≥ 9.2 mmol/L
(165 mg/dL)
≥ 8.0 mmol/L
(145 mg/dL)
NICE 2008;
WHO 1999*;
ADIPS 1998 (
Hoffman 1998)
75 g ≥ 7.0 mmol/L
(≥ 126 mg/dL)
- ≥ 11.1 mmol/L
(≥ 200 mg/dL)
-
NICE 2015 - 75 g ≥ 5.6 mmol/L
(≥ 101 mg/dL)
- ≥ 7.8 mmol/L
(140 mg/dL)
-
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Table 1. Examples of diagnostic criteria for gestational diabetes mellitus (Continued)
New Zealand
Ministry of
Health 2014*
50 g if HbA1c <
41 mmol/mol
(≥ 7.8 mmol/L;
≥ 140 mg/dL)
75 g ≥ 5.5 mmol/L
(≥ 99 mg/dL)
- ≥ 9.0 mmol/L
(≥ 162 mg/dL)
-
ADA American Diabetes Association (recommends either the one step or two step strategy)
IADPSG International Association of the Diabetes and Pregnancy Study Groups
ADIPS Australasian Diabetes in Pregnancy Society
ACOG American College of Obstetrics and Gynecology
NICE National Institute for Health and Care Excellence
*1 abnormal result required for diagnosis
ˆ2 or more abnormal results required for diagnosis
A P P E N D I C E S
Appendix 1. Clinical trial registry search strategy
gestational diabetes OR GDM
diabetes AND pregnancy
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N O T E S
The original review (Alwan 2009) has been split into three new reviews due to the complexity of the included interventions. The
following new review protocols are underway.
Lifestyle interventions for the treatment of women with gestational diabetes (this review)
Oral anti-diabetic pharmacological therapies for the treatment of women with gestational diabetes
Insulin for the treatment of women with gestational diabetes
There will be similarities in the background, methods and outcomes between these three systematic reviews.
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